Current mTOR inhibitor inclusive regimens may account for decreased number of tumors in kidney transplant recipients but also carry a risk of pulmonary toxicity manifesting histologically by pulmonary hemorrhage, organizing pneumonia and other less common histological patterns. Here, MTOR is linked to Pulmonary hemorrhage.